Project description:RNA epigenetics is perhaps the most recent field of interest for translational epigeneticists. RNA modifications create such an extensive network of epigenetically driven combinations whose role in physiology and pathophysiology is still far from being elucidated. Not surprisingly, some of the players determining changes in RNA structure are in common with those involved in DNA and chromatin structure regulation, while other molecules seem very specific to RNA. It is envisaged, then, that new small molecules, acting selectively on RNA epigenetic changes, will be reported soon, opening new therapeutic interventions based on the correction of the RNA epigenetic landscape. In this review, we shall summarize some aspects of RNA epigenetics limited to those in which the potential clinical translatability to cardiovascular disease is emerging.

| S-EPMC7014325 | biostudies-literature

Editorial: Cardiovascular responses and diseases at high altitude.

Project description: Not available

| S-EPMC9516092 | biostudies-literature

Editorial: Non-coding RNA in diabetes and cardiovascular diseases

Project description: Not available

| S-EPMC9939813 | biostudies-literature

Editorial: Regulation of Mitochondrial Function on Animal Diseases.

Project description: Not available

| S-EPMC9248764 | biostudies-literature

Epigenetic Biomarkers in Cardiovascular Diseases.

Project description:Cardiovascular diseases are the number one cause of death worldwide and greatly impact quality of life and medical costs. Enormous effort has been made in research to obtain new tools for efficient and quick diagnosis and predicting the prognosis of these diseases. Discoveries of epigenetic mechanisms have related several pathologies, including cardiovascular diseases, to epigenetic dysregulation. This has implications on disease progression and is the basis for new preventive strategies. Advances in methodology and big data analysis have identified novel mechanisms and targets involved in numerous diseases, allowing more individualized epigenetic maps for personalized diagnosis and treatment. This paves the way for what is called pharmacoepigenetics, which predicts the drug response and develops a tailored therapy based on differences in the epigenetic basis of each patient. Similarly, epigenetic biomarkers have emerged as a promising instrument for the consistent diagnosis and prognosis of cardiovascular diseases. Their good accessibility and feasible methods of detection make them suitable for use in clinical practice. However, multicenter studies with a large sample population are required to determine with certainty which epigenetic biomarkers are reliable for clinical routine. Therefore, this review focuses on current discoveries regarding epigenetic biomarkers and its controversy aiming to improve the diagnosis, prognosis, and therapy in cardiovascular patients.

| S-EPMC6795132 | biostudies-literature

Editorial: Epigenetic regulation and non-histone post-translational modification in cancer

Project description: Not available

| S-EPMC10116044 | biostudies-literature

Editorial: Molecular mechanisms of neuropsychiatric diseases.

Project description: Not available

| S-EPMC9773978 | biostudies-literature

Editorial: Autoimmune blistering diseases, volume II.

Project description: Not available

| S-EPMC10061345 | biostudies-literature

Editorial: Casein kinases in human diseases.

Project description: Not available